EPSRC logo

Details of Grant 

EPSRC Reference: EP/T020903/1
Title: U-care: Deep ultraviolet light therapies
Principal Investigator: Thomson, Professor RR
Other Investigators:
Bickmore, Professor W Stone, Dr JM Dhaliwal, Professor K
Wadsworth, Professor WJ Brennan, Dr P Akram, Dr ARK
Travers, Professor JC Duncan, Professor R Hand, Professor D
Paterson, Dr L Birks, Professor TA Knight, Professor J
Shephard, Professor JD
Researcher Co-Investigators:
Project Partners:
Aravind Eye Care System BTG plc (UK) Coherent UK Ltd
Glass Technology Services Ltd GTS GlobalSurg (UK) ICUsteps
Kings College London Lightpoint Medical Ltd M-Solv Ltd
NHS PowerPhotonic Ltd Renishaw plc (UK)
STFC Laboratories (Grouped) The Brain Tumour Charity University of Michigan
Department: Sch of Engineering and Physical Science
Organisation: Heriot-Watt University
Scheme: Programme Grants
Starts: 01 January 2021 Ends: 31 December 2025 Value (£): 6,132,366
EPSRC Research Topic Classifications:
Med.Instrument.Device& Equip. Optical Devices & Subsystems
EPSRC Industrial Sector Classifications:
Healthcare
Related Grants:
Panel History:  
Summary on Grant Application Form
The unique properties of light have made it central to our high-tech society. For example, our information-rich world is only enabled by the remarkable capacity of the fibre-optic network, where thin strands of glass are used to carry massive amounts of information around the globe as high-speed optical signals. Light also impacts areas of our society as diverse as laser-based manufacturing, solar energy, space-based remote sensing and even astronomy.

One area where the properties of light open up otherwise-impossible capabilities is medicine. In ophthalmology for example, lasers are routinely used to perform surgery on the eye through corneal reshaping. This involves two different lasers. In the first step, a laser producing very short pulses of infrared light cuts a flap in the front surface of the eye to provide access. In the second step, another laser producing longer pulses of ultraviolet (UV) light sculpts the shape of the cornea and correct focusing errors. The flap is then folded back into place so that the cornea can heal.

The two very-different laser systems in that example illustrate an important point: the effects of light on human tissues are highly-dependent on the specific properties of both the light and the tissues involved. To sculpt the cornea, the laser wavelength of 193 nm is in the deep UV region of the electromagnetic spectrum, much shorter than the visible range (380 - 740 nm) we are familiar with. This is because (unlike visible light) it is very efficiently absorbed by the cornea, so that essentially all the energy of the light is deposited at the surface. Thus only a very thin layer of tissue (a few microns thick) is removed, or "resected", with each pulse of light, facilitating very-precise shaping of the cornea and accurate adjustment of its focusing properties.

193 nm light can be generated by an ArF excimer gas laser, a >40 year-old technology producing a poor-quality low-brightness beam of light. This is suitable for corneal reshaping, but not for a range of other important therapies requiring higher-quality deep UV beams. Unfortunately, alternative ways to generate such short wavelengths are non-trivial, resulting in complex and expensive laser systems not suitable for widespread clinical uptake.

U-care aims to address this gap by exploiting cutting-edge techniques in laser physics. We will develop new sources of deep UV light which will be highly compact, robust and low cost. We will develop ways to deliver this light precisely to tissues, and work to understand in detail the biophysical mechanisms involved. Our efforts will focus on new therapies that target some of the biggest challenges facing medicine: cellular-precision cancer surgery, and the emergence of drug-resistant "super-bugs". Importantly, U-care will involve engineers and physical scientists working in close collaboration with clinicians and biomedical scientists to verify that the therapies we develop are effective and safe. By doing so in an integrated manner, we will drive our deep-UV light therapies towards healthcare impact and widespread use in the clinic by 2050.

Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Impacts
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Summary
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: http://www.hw.ac.uk